Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 21;29(1):209–220. doi: 10.1158/1078-0432.CCR-22-1654

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 4. Prognostic value of dynamic analysis of ctDNA. Kaplan–Meier estimates of EFS probabilities are shown for ctDNA-positive (at least one mutation detected in cfDNA) and ctDNA-negative patients at (A) mid-treatment, and (B) end-of-treatment. EFS differences between groups were tested using the log-rank test. The dynamic of ctDNA levels, measured as log10 fold-change, grouped by their (C) POD24 status and (D) response to treatment, is represented for each patient. ND, non-detected. — Prognostic value of dynamic analysis of ctDNA. Kaplan–Meier estimates of EFS probabilities are shown for ctDNA-positive (at least one mutation detected in cfDNA) and ctDNA-negative patients at (A) mid-treatment, and (B) end-of-treatment. EFS differences between groups were tested using the log-rank test. The dynamic of ctDNA levels, measured as log₁₀ fold-change, grouped by their (C) POD24 status and (D) response to treatment, is represented for each patient. ND, non-detected.